Navigation Links
Amgen Highlights Data to be Presented at 2011 European Multidisciplinary Cancer Congress
Date:9/23/2011

ing the risk of developing SREs in patients with multiple myeloma.

Amgen has also submitted marketing applications for XGEVA in Mexico, Russia, and Switzerland. In Japan, Amgen is working with its licensing partner, Daiichi Sankyo Company, Limited and a marketing application was submitted. In addition, Amgen and GlaxoSmithKline (GSK) have a collaboration agreement for the commercialization of XGEVA in a number of countries where Amgen does not currently have a commercial presence. In these countries, marketing applications are filed by GSK.

For more information on XGEVA, please visit www.XGEVA.com.

About VectibixVectibix injection for IV infusion is the first fully human anti-EGFR antibody approved by the U.S. Food and Drug Administration (FDA) for the treatment of mCRC. Vectibix received accelerated approval in the U.S. in September 2006 as a monotherapy for the treatment of patients with EGFR-expressing mCRC after disease progression on or following fluoropyrimidine-, oxaliplatin- and irinotecan-containing chemotherapy regimens.

The effectiveness of Vectibix as a single agent for the treatment of EGFR-expressing mCRC is based on progression-free survival. Currently no data are available that demonstrate an improvement in disease-related symptoms or increased survival with Vectibix.

Retrospective subset analyses of mCRC trials have not shown a treatment benefit for Vectibix in patients whose tumors had KRAS mutations in codon 12 or 13. Use of Vectibix is not recommended for the treatment of mCRC with these mutations.

In December 2007, the European Commission granted a conditional marketing authorization for Vectibix as a monotherapy for the treatment of patients with EGFR expressing mCRC with non-mutated (wild-type) KRAS after failure of fluoropyrimidine-, oxaliplatin- and irinotecan-containing chemotherapy regimens. Vectibix has been launched in more than 40 countries w
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Amgen to Present at the Bank of America Merrill Lynch Global Healthcare Conference
2. Amgen to Present at the Morgan Stanley Global Healthcare Conference
3. Amgen to Present at the Baird Healthcare Conference
4. Amgen to Present at the Stifel Nicolaus Healthcare Conference
5. Amgen Announces PDUFA Date for XGEVA® Supplemental Biologics License Application
6. Amgen’s Second Quarter 2011 Revenue Increased 4 Percent to $4.0 Billion
7. Amgen Announces Webcast of 2011 Second Quarter Financial Results
8. Amgen Resolves G-CSF Patent Litigation With Teva
9. Amgen and UCB Team Up With NASA on Final Space Shuttle Mission to Conduct Preclinical Test of Sclerostin Antibody on Bone Loss
10. Amgen Announces Modifications to U.S. Prescribing Information for Use of Erythropoiesis-Stimulating Agents in Chronic Kidney Disease
11. Teachers and Schools Across North America Receive $10,000 Amgen Award for Science Teaching Excellence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... analysis of Centers for Medicare and Medicaid Services, (CMS) ... percent of seniors chose lower-cost preferred pharmacy plans that ... The findings were released by Drug Channels . ... of Medicare Part D," said Pharmaceutical Care Management Association ...
(Date:1/23/2015)... a third of reproductive-aged women enrolled in Medicaid, and more ... prescription for an opioid pain medication each year during 2008-2012, ... Weekly Report (MMWR). Opioids are typically prescribed ... They are also found in some prescription cough medications. The ...
(Date:1/23/2015)... baseball,s all-time hits leader, is the new spokesperson for the ... has announced. "Pete,s a Hall of Famer in ... board with Myoflex," said Ducere Pharma Chief Executive Officer ... known across all generations. The passion and intensity that Pete ...
Breaking Medicine Technology:New Analysis: 81 Percent of Medicare Part D Seniors Choose "Preferred Pharmacy" Plans in 2015 2Opioid painkillers widely prescribed among reproductive age women 2Opioid painkillers widely prescribed among reproductive age women 3Pete Rose bets on Myoflex to relieve aches and pains 2
... historic open letter to the World Health Organization ... Drugs (CoMeD) , and the United Methodist Women are seeking ... vaccines.  Currently, the mercury-based preservative Thimerosal, which is 49% mercury ... much of the world, despite the fact that it is ...
... Texas, March 15, 2012  OxySure® Systems, Inc. (OTCBB: ... emergency oxygen solutions with its "oxygen from powder" ... a Supplier Agreement ("Agreement") with W.W. Grainger, Inc. ... (Logo:  http://photos.prnewswire.com/prnh/20120315/DA71084LOGO ) In terms ...
Cached Medicine Technology:Global Call for Mercury-free Vaccines Issued 2OxySure Systems Announces Supplier Agreement With Grainger 2OxySure Systems Announces Supplier Agreement With Grainger 3
(Date:1/22/2015)... Padre Murphy's and Owner Tom Boyle in ... Player Health Alliance (PPHA). The PPHA's passion for others' ... including NFL greats, treated for obstructive sleep apnea (OSA) has ... the cause in the valley. The most recent plans for ...
(Date:1/22/2015)... The Incredible Bulk is a revolutionary method put ... muscle by up to 30lbs in less than 12 weeks ... Stan Stevenson, prompting an investigative review. , “Our Incredible ... diet formula that allows the body to pack on a ...
(Date:1/22/2015)... January 22, 2015 Blue Cross and Blue ... who exemplify what it means to “Live Fearless.” ... people to share their stories about how they or someone ... inspired others by living in the moment. By telling these ...
(Date:1/22/2015)... New York (PRWEB) January 22, 2015 The ... ) in the U.S. District Court, Southern District of West ... Bard, Inc. in that proceeding’s first bellwether trial. In an ... for a new trial after finding that C.R. Bard had ...
(Date:1/22/2015)... TX (PRWEB) January 22, 2015 A ... issue of experience and person-centeredness in the long-term care ... towards action across the continuum. The paper, “The Power ... Continuum,” engages perspectives and practices of the patient, resident ...
Breaking Medicine News(10 mins):Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3
... release is available in French . ... of Canada today announced a new study that will ... David Sweet, Member of Parliament for Ancaster-Dundas-Flamborough-Westdale, made the ... of Health. , "This long-term study of 50,000 Canadians ...
... Pa., May 21 Elimination of funding ... proposed by the Senate Republican budget plan would end ... the rate of health care cost increases, improving quality ... said today.For the past two years the small "think ...
... MT. LAUREL, N.J., May 21 The Commission for ... Second Annual Patricia McCollom $1,000 Scholarship. August 1 is ... can be used to help cover the cost of ... will announce the scholarship winner in October, during Case ...
... Offer Unique Mobile Communication Solution That Improves Patient ... TCS Healthcare Technologies (TCS), an industry ... applications, announced today that they have added an ... care management software platform, supported by Life: WIRE(TM) ...
... and Boston believe they may have identified a gene that ... troublesome problem for people with diabetes. , The liver is ... (glucose) levels fall, the liver makes and releases more. In ... stop making sugar when it should, so blood sugar levels ...
... Foundation, Group Health, The Technology Alliance, UW TechTransfer ... An alliance of leaders in health care, business, ... chapter of the Partnership to Fight Chronic Disease ... 17th U.S. Surgeon General (2002-2006), President of the ...
Cached Medicine News:Health News:Government of Canada supports research to improve the health of future generations of Canadians 2Health News:Senate Republican Budget Would End Health Initiatives That Save Lives and Money 2Health News:Senate Republican Budget Would End Health Initiatives That Save Lives and Money 3Health News:Senate Republican Budget Would End Health Initiatives That Save Lives and Money 4Health News:CCMC Accepting Applications for Second Annual Patricia McCollom Scholarship Through Aug. 1 2Health News:TCS Healthcare Technologies to Offer Interactive Text Messaging As Part of Its Care Management Software Platform 2Health News:TCS Healthcare Technologies to Offer Interactive Text Messaging As Part of Its Care Management Software Platform 3Health News:Regulating the sugar factory in diabetes 2Health News:Technology Leaders, Patient Groups and Community Advocates Launch Effort to Tackle Chronic Disease Crisis in Washington State 2Health News:Technology Leaders, Patient Groups and Community Advocates Launch Effort to Tackle Chronic Disease Crisis in Washington State 3Health News:Technology Leaders, Patient Groups and Community Advocates Launch Effort to Tackle Chronic Disease Crisis in Washington State 4
Lyphochek Hemoglobin A2 Control is a human whole blood based product designed to monitor the performance of automated and manual procedures for the measurement of hemoglobin variants, including Hemog...
... Liquichek Hematology-16 Control ... use on most hematology ... to 16 parameters and ... differentials. This trilevel control ...
Liquichek Hematology Control (C) is an assayed hematology control for evaluating the performance of Coulter hematology instruments with complete CBC and VCS 5-part differential technology....
... Amplichek CT/GC Controls are liquid ... precision of test procedures that ... gonorrhoeae. Since they are specimen ... with either urine or endocervical/urethral ...
Medicine Products: